Skip to content

What is the best treatment after stroke?

Dual antiplatelet therapy in the acute phase following stroke and transient ischaemic attack (TIA): which is the best regimen?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN68019845
Enrollment
60
Registered
2008-05-30
Start date
2005-08-26
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic (stroke/TIA/amaurosis fugax) carotid artery stenosis Circulatory System Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction

Interventions

1. Aspirin (75 mg orally [po] once daily [od]) and dipyridamole SR (200 mg po twice daily [bd]) 2. Aspirin (75 mg po od) and clopidogrel (300 mg po loading dose following by 75 mg po od) Patients ran

Sponsors

St George's Heathcare NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Women or men aged greater than 18 years 2. Patients with greater than or equal to 50% carotid artery stenosis 3. Symptoms of TIA or stroke within the last month 4. Baseline magnetic resonance imaging (MRI) or computed tomography (CT) imaging has been performed 5. Consented to take part in the study

Exclusion criteria

Exclusion criteria: 1. Currently taking antiplatelet/antithrombotic medication other than aspirin (although low does prophylactic subcutaneous heparin for deep vein thrombosis [DVT] prophylaxis will be allowed) 2. Patients with prosthetic heart valves who have gaseous embolic signals 3. Where clopidogrel or dipyridamole is contra-indicated 4. Carotid endarterectomy planned within the next month 5. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
The number of embolic signals (using international consensus criteria) detected during transcranial doppler recording from ipsilateral middle cerebral artery at 48 hours after study entry.

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026